MA34586B1 - Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees - Google Patents

Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees

Info

Publication number
MA34586B1
MA34586B1 MA35763A MA35763A MA34586B1 MA 34586 B1 MA34586 B1 MA 34586B1 MA 35763 A MA35763 A MA 35763A MA 35763 A MA35763 A MA 35763A MA 34586 B1 MA34586 B1 MA 34586B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
crystalline particles
modified surface
micronized tacrolimus
tacrolimus crystalline
Prior art date
Application number
MA35763A
Other languages
English (en)
Inventor
Mohamed Amine Boujbel
Stephen Lukas
Karel Ren
Lassaad Boujbel
Original Assignee
Medis Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medis Lab filed Critical Medis Lab
Publication of MA34586B1 publication Critical patent/MA34586B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition pharmaceutique comprenant des particules cristallines de tacrolimus micronisé à surface modifiée ayant une valeur d90 comprise entre 2 ¼m et 10 ¼m.
MA35763A 2010-08-25 2011-08-24 Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees MA34586B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TN10391 2010-08-25
PCT/TN2011/000003 WO2012026896A1 (fr) 2010-08-25 2011-08-24 Particules cristallines de tacrolimus micronisé à surface modifiée et compositions pharmaceutiques associées

Publications (1)

Publication Number Publication Date
MA34586B1 true MA34586B1 (fr) 2013-10-02

Family

ID=44910279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35763A MA34586B1 (fr) 2010-08-25 2011-08-24 Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees

Country Status (2)

Country Link
MA (1) MA34586B1 (fr)
WO (1) WO2012026896A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439892B2 (en) 2013-05-16 2016-09-13 Surmodics, Inc. Macrolide particulates, methods for preparation, and medical devices associated therewith
JP6416242B2 (ja) 2013-06-12 2018-10-31 サーモディクス，インコーポレイティド 結晶性マクロライド微粒子を調製するための溶剤法、組成物、および微粒子を含む物品
EP3435988B1 (fr) 2016-03-31 2021-10-06 Surmodics, Inc. Composition de particules contenant un médicament et comprenant un agent cationique, dispositifs médicaux associés, et procédés de traitement
EP3554571B1 (fr) 2016-12-16 2024-11-13 Surmodics, Inc. Revêtements de particules d'agent actif hydrophobe et procédés de traitement
CN107595772B (zh) * 2017-09-26 2020-09-18 山东省药学科学院 一种他克莫司纳米混悬滴眼液的制备方法
CA3063417C (fr) * 2018-12-04 2023-01-03 Leon-Nanodrugs Gmbh Nanoparticules comprenant du tacrolimus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
PT2198858E (pt) * 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
EA013741B1 (ru) 2004-12-15 2010-06-30 Элан Фарма Интернэшнл Лтд. Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법

Also Published As

Publication number Publication date
WO2012026896A1 (fr) 2012-03-01

Similar Documents

Publication Publication Date Title
MA34586B1 (fr) Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
WO2012177757A3 (fr) Compositions de soin personnel comprenant des particules abrasives formées
BR112013017988A2 (pt) inibidores de bace-2 para o tratamento de distúrbios metabólicos
MA38039A1 (fr) Composés de céphem substitués en position 2
MX389751B (es) Composición farmacéutica y administraciones de la misma.
MA37610B1 (fr) Formulations de testostérone proliposomales
EP4342537A3 (fr) Compositions d'alcane semifluoré
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
BR112015022861A2 (pt) inibidores de bromodomínio
BR112014019667A2 (pt) formulação de anticorpo abeta
MX2011002065A (es) Composicion farmaceutica a base de progesterona micronizada y sus usos.
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
BR112014009376A2 (pt) composições
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
MY161390A (en) Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
IN2014CN00795A (fr)
JO3760B1 (ar) (مشتقات بريجنان مكثفة في الموضع 16، 17 ذات حلقة أيزوكسازوليدين بها استبدال عند - n كعوامل مضادة للالتهاب)
NZ708821A (en) Lfa-1 inhibitor formulations
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
WO2013057741A3 (fr) Compositions pharmaceutiques d'acide ursodésoxycholique
WO2011045760A3 (fr) Compositions d'olmésartan médoxomil micronisé
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
WO2012061015A3 (fr) Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase